CHI3L1 and myeloid sarcoma: CHI3L1 could be measured in serum and CSF, where increase throughout MS stages seems to be derived from the extension of diffuse brain inflammation associated with neurologic impairment rather than acute inflammation during relapses and the detrimental role of astrocyte activation in disease pathogenesis [3].